Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1595 • 2014 ACR/ARHP Annual Meeting
Economic Evaluation of Sequencing Strategies in the Treatment of Psoriatic Arthritis in the United States
Thomas Tencer¹, Zoe Clancy¹, Helene Cawston², Sandrine Cure³ and Frank Zhang¹, ¹33 Technology Drive, Celgene Corporation, Warren, NJ, ²OptumInsight, Nanterre, France, ³OptumInsight, Uxbridge, United Kingdom
Background/Purpose: In the treatment of psoriatic arthritis (PsA), switching between alternative biologic treatments is common. A cost-effectiveness model was developed to assess the impact of…
Abstract Number: 602 • 2014 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-Week) Improvements in Physical Function
Alvin Wells¹, Jacob A. Aelion², Adewale O. Adebajo³, Alan Kivitz⁴, Paul Bird⁵, ChiaChi Hu⁶, Randall M. Stevens⁶ and Christopher J. Edwards⁷, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²West Tennessee Research Institute, Jackson, TN, ³University of Sheffield, Sheffield, United Kingdom, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Combined Rheumatology Practice, Kogarah, Australia, ⁶Celgene Corporation, Warren, NJ, ⁷University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA).…
Abstract Number: 1590 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
Arthur Kavanaugh¹, Adewale O. Adebajo², Dafna D. Gladman³, Juan J. Gomez-Reino⁴, Stephan Hall⁵, Eric Lespessailles⁶, Philip J. Mease⁷, Georg A. Schett⁸, ChiaChi Hu⁹, Randall M. Stevens⁹ and Jürgen Wollenhaupt¹⁰, ¹University of California San Diego, La Jolla, CA, ²University of Sheffield, Sheffield, United Kingdom, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁵Cabrini Health and Monash University, Melbourne, Australia, ⁶University of Orléans, Orléans, France, ⁷Swedish Medical Center and University of Washington, Seattle, WA, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Schön Klinik Hamburg Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor that may modify the immune response, has been shown effective in psoriatic arthritis (PsA). PALACE 1 compared…
Abstract Number: 550 • 2014 ACR/ARHP Annual Meeting
Secukinumab, an Anti–Interleukin-17A Monoclonal Antibody, Improves Physical Function, Quality of Life and Work Productivity in Patients with Active Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
Vibeke Strand¹, Philip J. Mease², Iain B. McInnes³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Proton Rahman⁶, P. Nash⁷, Luminita Pricop⁸, Jiacheng Yuan⁹, Hanno Richards¹⁰ and Shephard Mpofu¹¹, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵University of California San Diego, La Jolla, CA, ⁶Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁷Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁸Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose Psoriatic arthritis (PsA) has a significant adverse effect on patients’ health-related quality of life (HRQoL), affecting their physical and emotional functioning and psychological health.…
Abstract Number: 1586 • 2014 ACR/ARHP Annual Meeting
Quantitative Proteomic Analysis of Synovial Fluid and Skin Identifies Putative Psoriatic Arthritis Biomarkers
Daniela Cretu¹, Kun Liang², Dafna D. Gladman³, Eleftherios Diamandis⁴ and Vinod Chandran³, ¹Laboratory Medicine and Pathobiology, Unviersity of Toronto, Mount Sinai Hospital, Ontario, Canada, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Background/Purpose Psoriatic arthritis (PsA) is a unique form of arthritis occurring in 30% of psoriasis patients. There is a high prevalence of undiagnosed PsA in…
Abstract Number: 548 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Arthur Kavanaugh¹, Maurizio Cutolo², Philip J. Mease³, Dafna D. Gladman⁴, Adewale O. Adebajo⁵, Juan Gomez-Reino⁶, Jürgen Wollenhaupt⁷, Georg A. Schett⁸, Eric Lespessailles⁹, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher Edwards¹¹ and Charles A. Birbara¹², ¹University of California San Diego, La Jolla, CA, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Sheffield, Sheffield, United Kingdom, ⁶Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁷Teaching Hospital of the University of Hamburg, University of Hamburg, Hamburg, Germany, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…
Abstract Number: 1572 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
Christopher J. Edwards¹, Jacob A. Aelion², Adewale O. Adebajo³, Alan Kivitz⁴, Paul Bird⁵, ChiaChi Hu⁶, Randall M. Stevens⁶ and Alvin Wells⁷, ¹University Hospital Southampton, Southampton, United Kingdom, ²West Tennessee Research Institute, Jackson, TN, ³University of Sheffield, Sheffield, United Kingdom, ⁴Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁵Combined Rheumatology Practice, Kogarah, Australia, ⁶Celgene Corporation, Warren, NJ, ⁷Rheumatology & Immunotherapy Center, Franklin, WI
Background/Purpose: Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA).…
Abstract Number: 537 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial
Alice B. Gottlieb¹, Philip J. Mease², Iain B. McInnes³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Proton Rahman⁶, Peter Nash⁷, Luminita Pricop⁸, Jiacheng Yuan⁹, Hanno Richards¹⁰ and Shephard Mpofu¹¹, ¹Tufts Medical Center, Boston, MA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁷University of Queensland, Brisbane, Australia, ⁸Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose Reducing the burden of skin manifestations of psoriatic arthritis (PsA) is an important aspect of disease management. Secukinumab, a human anti–IL-17A monoclonal antibody, has…
Abstract Number: 1565 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Improvement of Pain, Fatigue, and Disability in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Dafna D. Gladman¹, Vibeke Strand², Arthur Kavanaugh³, Philip J. Mease⁴, Christopher J. Edwards⁵, Maurizio Cutolo⁶, Frédéric Lioté⁷, Paul Bird⁸, Randall M. Stevens⁹, Lichen Teng⁹, Marla Hochfeld⁹ and Georg A. Schett¹⁰, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Stanford University, Portola Valley, CA, ³University of California San Diego, La Jolla, CA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵University Hospital Southampton, Southampton, United Kingdom, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁷Rheumatology Department, University Paris Diderot, Paris, France, ⁸Combined Rheumatology Practice, Kogarah, Australia, ⁹Celgene Corporation, Warren, NJ, ¹⁰Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…
Abstract Number: 463 • 2014 ACR/ARHP Annual Meeting
Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Jonathan Kay¹, Roy Fleischmann², Edward C. Keystone³, Elizabeth C. Hsia^4,5, Neil Goldstein⁴, Benjamin Hsu⁴, Yiying Zhou⁴, Jürgen Braun⁶ and Arthur Kavanaugh⁷, ¹UMass Memorial Medical Center, Worcester, MA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷University of California San Diego, La Jolla, CA
Background/Purpose: To present an analysis of pooled data through approx 5yrs of follow-up from 5 completed golimumab(GLM) Ph3 SC trials across rheumatological indications. Methods: SC…
Abstract Number: 1564 • 2014 ACR/ARHP Annual Meeting
Long-Term (104-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial and Open-Label Extension
Philip J. Mease¹, Adewale O. Adebajo², Dafna D. Gladman³, Juan J. Gomez-Reino⁴, Stephan Hall⁵, Arthur Kavanaugh⁶, Eric Lespessailles⁷, Georg A. Schett⁸, Kamal Shah⁹, Randall M. Stevens⁹, Lichen Teng⁹ and Jürgen Wollenhaupt¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Sheffield, Sheffield, United Kingdom, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁵Cabrini Health and Monash University, Melbourne, Australia, ⁶University of California San Diego, La Jolla, CA, ⁷University of Orléans, Orléans, France, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Schön Klinik Hamburg Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), a phosphodiesterase 4 inhibitor, helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA). PALACE 1,…
Abstract Number: L1 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing
Iain B. McInnes^1,2, Philip J. Mease³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Christopher T. Ritchlin⁶, Proton Rahman⁷, Désirée van der Heijde⁸, Robert B. M. Landewé⁹, Philip G. Conaghan¹⁰, Hanno Richards¹¹, Gregory Ligozio¹², Luminita Pricop¹³ and Shephard Mpofu¹⁴, ¹University of Glasgow, Glasgow, Scotland, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵UC San Diego School of Medicine, La Jolla, CA, ⁶Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁷Memorial University, St John's, NF, Canada, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ¹⁰University of Leeds, Leeds, United Kingdom, ¹¹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹³Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a human anti–IL-17A monoclonal antibody, has shown efficacy in the treatment of psoriasis in phase 3 studies with subcutaneous (s.c.) dosing as well…
Abstract Number: 3010 • 2014 ACR/ARHP Annual Meeting
The Development and Evaluation of a Self-Monitoring and Patient-Initiated Follow-up Service for People with Rheumatoid or Psoriatic Arthritis on Methotrexate
Hayley McBain^1,2, Michael Shipley³, Abigail Olaleye³, Samantha Moore⁴, Shashi Hirani⁵ and Stanton Newman⁶, ¹Health Services Research and Management Division, City University London, London, United Kingdom, ²Community Health Newham, East London Foundation Trust, London, United Kingdom, ³University College Hospital London, London, United Kingdom, ⁴Rheumatology, University College London, London, United Kingdom, ⁵City University London, London, United Kingdom, ⁶School of Community & Health Sciences, City University London, London, United Kingdom
Background/Purpose: Patient-initiated services in rheumatology have been found to be cost-saving without compromising the clinical or psychosocial well-being of patients with rheumatoid arthritis. Self-monitoring is…
Abstract Number: 1579 • 2014 ACR/ARHP Annual Meeting
Change in Weight from Baseline with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Philip J. Mease¹, Dafna D. Gladman², Arthur Kavanaugh³, Adewale O. Adebajo⁴, Juan Gomez-Reino⁵, Jurgen Wollenhaupt⁶, Georg A. Schett⁷, Kamal Shah⁸, ChiaChi Hu⁸, Randall M. Stevens⁸, Christopher Edwards⁹ and Charles A. Birbara¹⁰, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of California San Diego, La Jolla, CA, ⁴University of Sheffield, Sheffield, United Kingdom, ⁵Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Schön-Klinik, Hamburg, Germany, ⁷Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Celgene Corporation, Warren, NJ, ⁹Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹⁰University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR) is a PDE4 inhibitor that helps regulate the immune response. PALACE 1, 2, and 3 assessed the efficacy and safety of APR…
Abstract Number: L22 • 2014 ACR/ARHP Annual Meeting
Long-Term (104-Week) Safety and Efficacy of Monotherapy with Apremilast in DMARD-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (PALACE 4)
Alvin Wells¹, Christopher Edwards², Adewale O. Adebajo³, Alan J. Kivitz⁴, Paul Bird⁵, Kamal Shah⁶, ChiaChi Hu⁶, Randall M. Stevens⁶ and Jacob A. Aelion⁷, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²University Hospital Southampton, Southampton, United Kingdom, ³University of Sheffield, Sheffield, United Kingdom, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Combined Rheumatology Practice, Sydney, Australia, ⁶Celgene Corporation, Warren, NJ, ⁷West Tennessee Research Institute, Jackson, TN
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes joint inflammation and other manifestations of psoriatic arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].